A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2009
12/23/2009	WO2009155402A1 Thiazolyl- and oxazolyl-isoquinolinones and methods for using them
12/23/2009	WO2009155335A2 Conjugates of 19f mr imaging tracers and chemotherapeutic agents for drug quantification and drug dose individualization
12/23/2009	WO2009155135A1 Composition comprising liposome-entrapped doxorubicin and methods of admnistration for treatment of multiple myeloma
12/23/2009	WO2009155121A2 Inhibitors of pi3 kinase
12/23/2009	WO2009155070A2 Compositions and methods for treatment of inflammation and hyperkeratotic lesions
12/23/2009	WO2009155055A2 Methods of effecting wnt signaling through dkk structural analysis
12/23/2009	WO2009155042A1 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
12/23/2009	WO2009155025A1 Methods of treating a meiotic kinesin-associated disease
12/23/2009	WO2009154835A2 Compositions and methods related to mir-16 and therapy of prostate cancer
12/23/2009	WO2009154741A1 Thiophene or thiazole derivatives and their use as pi3k inhibitors
12/23/2009	WO2009154739A2 Smoothened receptor modulators
12/23/2009	WO2009154737A1 Boronate ester compounds and pharmaceutical compositions thereof
12/23/2009	WO2009154697A2 Disc-1 pathway activators in the control of neurogenesis
12/23/2009	WO2009154645A1 Methods for the treatment of central nervous system tumors
12/23/2009	WO2009154565A1 Combination therapies against cancer
12/23/2009	WO2009154248A1 Pharmaceutical composition for treatment or prevention of hbv infection
12/23/2009	WO2009154230A1 Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
12/23/2009	WO2009153992A1 Cdca1 epitope peptides and vaccines containing the same
12/23/2009	WO2009153897A1 Stemonamide synthesis intermediate and pharmaceutical composition for prevention and/or treatment of cancer
12/23/2009	WO2009153597A2 Composition and process - 356
12/23/2009	WO2009153592A1 Pyrazole compounds 436
12/23/2009	WO2009153589A1 Pyridine compounds
12/23/2009	WO2009153566A1 Cyp26 inhibitors
12/23/2009	WO2009153463A1 Immunogenic peptides derived from the midkine protein, as an anticancer vaccine
12/23/2009	WO2009153418A1 Harp peptides inhibiting tumour growth
12/23/2009	WO2009153319A1 Anti-tumour compositions and methods
12/23/2009	WO2009153313A1 2 -arylaminoquinazolines for treating proliferative diseases
12/23/2009	WO2009153043A1 Combinations comprising methotrexate and dhodh inhibitors
12/23/2009	WO2009152920A1 3-(3-pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazine derivatives as met kinase inhibitors
12/23/2009	WO2009152824A1 Heterocyclic derivatives as iap binding compounds
12/23/2009	WO2009152783A1 Inhibitors of the epidermal growth factor receptor (egfr) with cytostatic action and their uses in tumour therapy
12/23/2009	WO2009152735A1 Histone deacetylase inhibitors and uses thereof
12/23/2009	WO2009152712A1 Vinflunine salts, preparation process and pharmaceutical composition thereof
12/23/2009	WO2009152691A1 A polyglycol modified chitosan oligosaccharide fatty acid graft, preparation method thereof and use of the same
12/23/2009	WO2009152610A1 Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
12/23/2009	WO2009152584A1 Synthesis of ageladine a and analogs thereof
12/23/2009	WO2009134725A3 Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
12/23/2009	WO2009129408A3 Compositions and methods for treating pathologic angiogenesis and vascular permeability
12/23/2009	WO2009117828A8 Saponin extract from saponaria spp. and uses thereof
12/23/2009	WO2009115321A8 Imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators
12/23/2009	WO2009114816A3 Therapeutic cancer antigens
12/23/2009	WO2009114462A3 Local delivery of chemotherapeutic agents to skeletal metastases
12/23/2009	WO2009113108A4 Styrene maleic anhydride based formulation for male contraception and prostate cancer
12/23/2009	WO2009066060A3 4-substituted-6-isopropyl-benzene-1,3-diol compounds and their use
12/23/2009	WO2009060186A8 Sulfonated precursors of thymidine for the treatment of epithelial hyperplasias
12/23/2009	WO2008155140A8 Alkynylpyrimidines as tie2 kinase inhibitors
12/23/2009	WO2008091643A3 Evaluating synergy of combinations comprising an antibody in immune suppressive pathways concurrent to immunotherapy
12/23/2009	WO2008041053A3 Inhibitors of vegf receptor and hgf receptor signaling
12/23/2009	WO2000015247A8 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
12/23/2009	EP2135881A1 Antibodies binding to the tumour associated antigen TAT10772 for the diagnosis and treatment of tumor
12/23/2009	EP2135867A1 Trans-9, 10-dehydroepothilone C and trans-9, 10-dehydroepothilone D, analogs thereof and methods of making the same
12/23/2009	EP2135623A1 Method of treatment of a BCL-2 disorder using BCL-2 antisense oligomers
12/23/2009	EP2135611A1 Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
12/23/2009	EP2135610A1 Combination comprising DHODH inhibitors and methotrexate
12/23/2009	EP2135605A2 Therapeutic delivery of carbon monoxide
12/23/2009	EP2135604A1 Infusion preparation for cancer patient
12/23/2009	EP2135600A1 Targeting agent for cancer cell or cancer-associated fibroblast
12/23/2009	EP2134843A1 Kunitz-type recombinant inhibitor
12/23/2009	EP2134746A1 Monoclonal human tumor-specific antibody
12/23/2009	EP2134736A1 Five- and six-membered conformationally locked 2',4'- carbocyclic ribo-thymidines for the treatment of infections and cancer
12/23/2009	EP2134715A2 O6-alkylguanine-dna alkyltransferase inactivators
12/23/2009	EP2134686A1 Piperidinones useful in the treatment of inflammation
12/23/2009	EP2134685A1 7-nonsubstituted indole mcl-1 inhibitors
12/23/2009	EP2134684A2 7-substituted indole mcl-1 inhibitors
12/23/2009	EP2134374A2 Sirna-mediated silencing of genes for treating chemotherapeutic drug-resistant epithelial tumours
12/23/2009	EP2134368A1 Homeopathic medicament useful for immunomodulation
12/23/2009	EP2134367A2 Integrated photoactive peptides and uses thereof
12/23/2009	EP2134356A2 Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy
12/23/2009	EP2134348A1 Weekly administration of dipeptidyl peptidase inhibitors
12/23/2009	EP2134346A1 Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1
12/23/2009	EP2134341A2 Method of treating cell proliferative disorders using growth hormone secretagogues
12/23/2009	EP2134338A1 Hydroquinone ansamycin formulations
12/23/2009	EP2134322A1 Intravesical apaziquone administration following transurethral resection for treating cancer
12/23/2009	EP1879901B1 Pyrrolobenzodiazepines
12/23/2009	EP1549651B1 Pyrimidopyrimidones as kinase inhibitors
12/23/2009	EP1483297B1 Antibodies derived from anti ed-b l19 and targeting tumor vasculature
12/23/2009	EP1483251B1 C3-cyano epothilone derivatives
12/23/2009	EP1450822B1 Polyalkylene oxide conjugates of thiol-containing drugs
12/23/2009	EP1421174B1 Hematopoietic cell e-selectin/l-selectin ligand polypeptides and methods of use thereof
12/23/2009	EP1296972B1 Arylmethylamine derivatives for use as tryptase inhibitors
12/23/2009	EP1274861B1 Compositions and methods for identifying and targeting cancer cells
12/23/2009	EP1259487B1 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
12/23/2009	EP1232757B1 Agents for diseases in association with decrease in bone mass
12/23/2009	CN201366104Y Externally-applied gynecological suppository with active protein and nano-silver
12/23/2009	CN101611059A Antibodies against insulin-like growth factor I receptor and uses thereof
12/23/2009	CN101611058A PRLR-specific antibody and uses thereof
12/23/2009	CN101611055A Human antibodies to human DELTA like ligand 4
12/23/2009	CN101611046A Antiviral nucleoside analogs
12/23/2009	CN101611041A Fused heterocyclic compound
12/23/2009	CN101611036A Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
12/23/2009	CN101611011A Chemical compounds
12/23/2009	CN101611005A Substituted acetophenones useful as PDE4 inhibitors
12/23/2009	CN101610997A Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors
12/23/2009	CN101610777A Preventing or reducing oxidative stress or oxidative cell injury by the administration of a water-insoluble cellulose derivative
12/23/2009	CN101610776A Combination comprising CNDAC (2'-cyano-2'-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agent
12/23/2009	CN101610771A Therapeutic agent for liver cancer
12/23/2009	CN101610768A Method of inhibiting C KIT kinase
12/23/2009	CN101610759A Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs
12/23/2009	CN101610688A Polyphenol extraction process
12/23/2009	CN101608182A Oncogene, recombinant protein derived therefrom, and uses thereof

1 ... 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 ... 2211